Human antibodies that bind human tnf.alpha.
CA 2243459 C · Owner: Wilton, Alison J. · Inventors: Schoenhaut, David; Mankovich, John A.; Labkovsky, Boris
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Human antibodies, preferably recombinant human antibodies that specifically , bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha.(e.g. Kd = 10-8 M or less) a , slow off rate for hTNF.alpha. dissociation (e.g. Koff = 10-3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity e.g. in a , human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 1997 and granted September 17, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 10, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.